Target intelligence / Profile preview

Rabphilin-3A (RPH3A)

Target
RPH3A
Molecular classification
Other (effector protein for Rab GTPases, synaptic vesicle-associated protein)
01

Overview

Rabphilin-3A is a synaptic vesicle-associated effector protein with multiple functional domains. It was originally identified as a binding partner of the small GTPases Rab3A and Rab27A, which localize to secretory vesicles in neurons and neuroendocrine cells. Rabphilin-3A interacts with GTP-bound Rab proteins via its N-terminal Rab-binding domain and links vesicles to the actin cytoskeleton through α-actinin binding. Its C-terminal C2 domains bind calcium, phospholipids, and SNAP-25. Rabphilin-3A's main biological role is to regulate both exocytosis and endocytosis of vesicles, especially facilitating SNARE complex assembly for neurotransmitter release. It acts at distinct stages in the vesicular trafficking pathway, influencing vesicle docking, fusion, and membrane retrieval, but does not function as a receptor, enzyme, transporter, or transcription factor[1][2].

Other names
Rabphilin-3ARPH3AKIAA0985Exophilin-1RabphilinRabphilin 3A homolog
02

Mechanism of action

Not applicable; drugs do not directly target this molecule. Its mechanism involves regulation of vesicle docking and fusion through protein-protein interactions.

03

Biological functions

Regulates synaptic vesicle exocytosis by interacting with Rab3A and Rab27AFacilitates SNARE-dependent vesicle fusion by binding SNAP-25Binds calcium, phospholipids, and cytoskeletal proteinsModulates both exocytosis and endocytosis of vesiclesRegulates actin cytoskeleton and vesicle trafficking
04

Disease associations

Neurodegenerative disease (implicated in neuronal vesicle trafficking defects—no established direct disease association as a biomarker or target)Other (critical for neurotransmitter and hormone release in neurons and neuroendocrine cells)
05

Safety considerations

None reported; Rabphilin-3A is not established as a therapeutic target, so safety data pertaining to its modulation are unavailable.
06

Interacting drugs

None known; Rabphilin-3A is not a current drug target, and there are no drugs directly interacting with it
07

Biomarkers

None established for patient selection or therapeutic efficacy

Beyond the preview

Go deeper on Rabphilin-3A (RPH3A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rabphilin-3A (RPH3A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call